Jeil Pharmaceutical Co., Ltd. – Product Pipeline Review

Global Markets Direct’s, ‘Jeil Pharmaceutical Co., Ltd. – Product Pipeline Review – 2016’, provides an overview of the Jeil Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Jeil Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Jeil Pharmaceutical Co., Ltd.

The report provides overview of Jeil Pharmaceutical Co., Ltd. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Jeil Pharmaceutical Co., Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Jeil Pharmaceutical Co., Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Jeil Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Jeil Pharmaceutical Co., Ltd.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Jeil Pharmaceutical Co., Ltd.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Jeil Pharmaceutical Co., Ltd. Snapshot 6

Jeil Pharmaceutical Co., Ltd. Overview 6

Key Information 6

Key Facts 6

Jeil Pharmaceutical Co., Ltd. - Research and Development Overview 7

Key Therapeutic Areas 7

Jeil Pharmaceutical Co., Ltd. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Combination Treatment Modalities 12

Jeil Pharmaceutical Co., Ltd. - Pipeline Products Glance 13

Jeil Pharmaceutical Co., Ltd. - Late Stage Pipeline Products 13

Phase III Products/Combination Treatment Modalities 13

Jeil Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products 14

Phase I Products/Combination Treatment Modalities 14

Jeil Pharmaceutical Co., Ltd. - Early Stage Pipeline Products 15

Preclinical Products/Combination Treatment Modalities 15

Discovery Products/Combination Treatment Modalities 16

Jeil Pharmaceutical Co., Ltd. - Drug Profiles 17

(solifenacin succinate + tamsulosin hydrochloride) 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

JLP-1401 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

metformin hydrochloride + rosuvastatin calcium 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

JJP-1305 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

JPI-289 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

JGK-263 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

JLP-1601 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

JLP-1604 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

JP-1366 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

JP-2266 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

JPI-547 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Small Molecule for Degenerative Arthritis 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Small Molecule for Hypertriglyceridaemia 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Stem Cell Therapy for Parkinson's Disease and Age-Related Macular Degeneration 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

JLP-1602 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

JLP-1603 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Small Molecule to Inhibit FLT3 for Acute Myeloid Leukemia 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Small Molecules for Neuropathic Pain 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Jeil Pharmaceutical Co., Ltd. - Pipeline Analysis 35

Jeil Pharmaceutical Co., Ltd. - Pipeline Products by Target 35

Jeil Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 37

Jeil Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type 38

Jeil Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action 39

Jeil Pharmaceutical Co., Ltd. - Recent Pipeline Updates 40

Jeil Pharmaceutical Co., Ltd. - Dormant Projects 41

Jeil Pharmaceutical Co., Ltd. - Company Statement 42

Jeil Pharmaceutical Co., Ltd. - Locations And Subsidiaries 43

Head Office 43

Other Locations & Subsidiaries 43

Appendix 45

Methodology 45

Coverage 45

Secondary Research 45

Primary Research 45

Expert Panel Validation 45

Contact Us 45

Disclaimer 46

List of Tables

List of Tables

Jeil Pharmaceutical Co., Ltd., Key Information 6

Jeil Pharmaceutical Co., Ltd., Key Facts 6

Jeil Pharmaceutical Co., Ltd. – Pipeline by Indication, 2016 8

Jeil Pharmaceutical Co., Ltd. – Pipeline by Stage of Development, 2016 10

Jeil Pharmaceutical Co., Ltd. – Monotherapy Products in Pipeline, 2016 11

Jeil Pharmaceutical Co., Ltd. – Combination Treatment Modalities in Pipeline, 2016 12

Jeil Pharmaceutical Co., Ltd. – Phase III, 2016 13

Jeil Pharmaceutical Co., Ltd. – Phase I, 2016 14

Jeil Pharmaceutical Co., Ltd. – Preclinical, 2016 15

Jeil Pharmaceutical Co., Ltd. – Discovery, 2016 16

Jeil Pharmaceutical Co., Ltd. – Pipeline by Target, 2016 36

Jeil Pharmaceutical Co., Ltd. – Pipeline by Route of Administration, 2016 37

Jeil Pharmaceutical Co., Ltd. – Pipeline by Molecule Type, 2016 38

Jeil Pharmaceutical Co., Ltd. – Pipeline Products by Mechanism of Action, 2016 39

Jeil Pharmaceutical Co., Ltd. – Recent Pipeline Updates, 2016 40

Jeil Pharmaceutical Co., Ltd. – Dormant Developmental Projects,2016 41

Jeil Pharmaceutical Co., Ltd., Other Locations 43

List of Figures

List of Figures

Jeil Pharmaceutical Co., Ltd. – Pipeline by Top 10 Indication, 2016 8

Jeil Pharmaceutical Co., Ltd. – Pipeline by Stage of Development, 2016 10

Jeil Pharmaceutical Co., Ltd. – Monotherapy Products in Pipeline, 2016 11

Jeil Pharmaceutical Co., Ltd. – Pipeline by Target, 2016 35

Jeil Pharmaceutical Co., Ltd. – Pipeline by Route of Administration, 2016 37

Jeil Pharmaceutical Co., Ltd. – Pipeline by Molecule Type, 2016 38

Jeil Pharmaceutical Co., Ltd. – Pipeline Products by Mechanism of Action, 2016 39

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports